• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

昂丹司琼的血浆测定及药代动力学

The determination in plasma and pharmacokinetics of ondansetron.

作者信息

Colthup P V, Palmer J L

机构信息

Glaxo Group Research Ltd., Ware, Hertfordshire, U.K.

出版信息

Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S71-4.

PMID:2533903
Abstract

High performance liquid chromatography has been found to be an accurate method for determination of ondansetron in plasma. Within a single assay, and between assays, the differences between theoretical and observed means obtained from analysis of spiked samples were low and good precision was obtained. The method has been used to assay several thousand samples from subjects included in pharmacokinetic studies. The pharmacokinetic profile of ondansetron has been established following single and multiple oral dosing and intravenous infusions.

摘要

高效液相色谱法已被证明是测定血浆中昂丹司琼的准确方法。在单次测定以及不同次测定之间,加标样品分析所得理论均值与观测均值之间的差异较小,且精密度良好。该方法已用于药代动力学研究中数千例受试者样本的分析。在单次和多次口服给药以及静脉输注后,已确定了昂丹司琼的药代动力学特征。

相似文献

1
The determination in plasma and pharmacokinetics of ondansetron.昂丹司琼的血浆测定及药代动力学
Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S71-4.
2
The metabolism of ondansetron.
Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S75-7.
3
Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.昂丹司琼在大鼠体内的非剂量依赖性药代动力学:肝脏和肠道首过效应对低生物利用度的影响
Biopharm Drug Dispos. 2008 Oct;29(7):414-26. doi: 10.1002/bdd.628.
4
Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection.采用带紫外检测的高效液相色谱法同时测定人血浆中昂丹司琼和托烷司琼的含量。
Biomed Chromatogr. 2002 May;16(3):187-90. doi: 10.1002/bmc.125.
5
The clinical pharmacology of ondansetron.昂丹司琼的临床药理学。
Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S21-4; discussion S25-7.
6
Development and validation of a rapid 96-well format based liquid-liquid extraction and liquid chromatography-tandem mass spectrometry analysis method for ondansetron in human plasma.一种基于96孔板快速液液萃取和液相色谱-串联质谱法测定人血浆中昂丹司琼的分析方法的建立与验证
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 19;836(1-2):79-82. doi: 10.1016/j.jchromb.2006.03.032. Epub 2006 Apr 11.
7
Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly.
J Pharm Sci. 1991 Sep;80(9):868-71. doi: 10.1002/jps.2600800913.
8
Pharmaceutical development of ondansetron injection.昂丹司琼注射液的药物研发
Eur J Cancer Clin Oncol. 1989;25 Suppl 1:S67-9.
9
Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects.
Biopharm Drug Dispos. 1996 Apr;17(3):249-58. doi: 10.1002/(SICI)1099-081X(199604)17:3<249::AID-BDD952>3.0.CO;2-E.
10
Quantitative determination of ondansetron in human plasma by enantioselective liquid chromatography-tandem mass spectrometry.采用对映体选择性液相色谱-串联质谱法对人血浆中昂丹司琼进行定量测定。
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Mar 15;864(1-2):129-36. doi: 10.1016/j.jchromb.2008.02.002. Epub 2008 Feb 12.

引用本文的文献

1
Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome.昂丹司琼在孕妇和新生儿中的药代动力学:寻求新生儿戒断综合征的新治疗方法。
Clin Pharmacol Ther. 2015 Feb;97(2):167-76. doi: 10.1002/cpt.5. Epub 2014 Dec 4.
2
Placental transfer of ondansetron during early human pregnancy.
Clin Pharmacokinet. 2006;45(4):419-23. doi: 10.2165/00003088-200645040-00006.
3
Cardiovascular stability with rapid intravenous infusion of ondansetron.快速静脉输注昂丹司琼时的心血管稳定性。
Can J Anaesth. 1993 May;40(5 Pt 1):448-52. doi: 10.1007/BF03009516.
4
Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.昂丹司琼。其在化疗引起的恶心呕吐及术后恶心呕吐治疗应用的最新进展。
Drugs. 1993 Jun;45(6):931-952. doi: 10.2165/00003495-199345060-00006.
5
Ondansetron clinical pharmacokinetics.昂丹司琼的临床药代动力学。
Clin Pharmacokinet. 1995 Aug;29(2):95-109. doi: 10.2165/00003088-199529020-00004.
6
Ondansetron. Therapeutic use as an antiemetic.昂丹司琼。作为止吐药的治疗用途。
Drugs. 1991 Apr;41(4):574-95. doi: 10.2165/00003495-199141040-00006.
7
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.不同剂量昂丹司琼持续输注或单次静脉给药对顺铂所致急性呕吐的止吐疗效比较。一项多中心、双盲、随机、平行组研究。昂丹司琼研究组。
Br J Cancer. 1992 Jul;66(1):192-7. doi: 10.1038/bjc.1992.241.
8
Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers.
Psychopharmacology (Berl). 1992;109(4):497-8. doi: 10.1007/BF02247730.
9
Pharmacokinetic optimisation of antiemetic therapy.止吐疗法的药代动力学优化
Clin Pharmacokinet. 1992 Aug;23(2):147-60. doi: 10.2165/00003088-199223020-00006.